B+
Bull case
25%
Probability
Target price
$3.80
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
CTMX
CytomX TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The year-end Varseta-M update could support dose selection and the planned registrational study. CytomX also announced FDA Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer; the designation is not approval [#IR-2026-08-27] (https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-fda-fast-track-designation).
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.8.
What can break
FDA alignment, treatment-line choice, comparator, and timing of the planned registrational study remain uncertain [#SEC-8K-2026-08-06].
Momentum
20
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.60 · Bull $3.80 · Bear $1.20Analysis 2026-10-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.25
Why
Momentum20 · Δ7d +3.2
Value41 · Δ7d -0.1
Sentiment63 · Δ7d +13.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +13.8.
Contradictions & invalidation
- • FDA alignment, treatment-line choice, comparator, and timing of the planned registrational study remain uncertain [#SEC-8K-2026-08-06].
- • Fast Track designation does not guarantee accelerated development, approval, or commercial uptake.
- • The valuation remains concentrated in unproven clinical programs.
Catalyst clock
2026-12-31
Varseta-M colorectal-cancer data and dose selection
Lead driver: Sentiment · See AI snapshot
Momentum
20
8% active weight
Current posture
7d trendSoftening
Δ7d
+3.2
Δ21d
+7.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
63
45% active weight
Current posture
7d trendImproving
Δ7d
+13.8
Δ21d
+0.0
Why this grade
Composite grade D. Momentum 19.5 / Value 40.6 / Sentiment 62.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$505.53M
Beta
2.44
Shares Out
217.9M
P/E (TTM)
10.2
P/S (TTM)
6.14
P/FCF (TTM) · Derived
-5.07
Rev YoY
-92.4%
EPS YoY
+7766.7%
Gross Margin
+94.9%
Op Margin
-476.7%
Net Debt
-$132.81M
Current Ratio
9.36
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data